Heart Failure Therapy: New Weapons, Old Foe

Saturday, February 5, 2022 – 11:00 AM-12:00 PM
 

This course will review recently published literature highlighting the use of ARNI and SGLT2 inhibitors in patients with heart failure with reduced and preserved ejection fraction. Strategies to maximize guideline directed medical therapy for heart failure with reduced ejection fraction will also be discussed.
 

 

Learning Objectives - Pharmacists
Upon successful completion of this
application-based CPE activity, participants should be able to:

  1. Identify candidates for ARNI and SGLT2 inhibitor therapy in patients with HFrEF.
  2. Discuss strategies to maximize guideline directed medical therapy for HFrEF.
  3. Explain the updated labeling indication for ARNI therapy in patients with chronic heart failure.
  4. Characterize appropriate opportunities to collaborate with heart failure specialists to facilitate referrals of eligible patients.
  5. Create a care plan for a patient with heart failure that includes an SGLT2 inhibitor as appropriate therapy.

0.1 CEU/1 hr
UAN: 0107-0000-22-010-L01-P


Laura Czerniak, PharmD, BCPS, BCCP
Clinical Specialist
University of Iowa Hospitals and Clinics